Largest yet life science investor event opens in Victoria


Australia’s biggest yet biotech investment event, Australia Biotech Invest 2017, has opened today in Melbourne, attracting 29 presenting companies and 310 delegates.

The event provides a platform for Australian life science companies to showcase their innovation for investment and partnerships – and contribute to an innovation-friendly ecosystem.

Australia Biotech Invest 2017 has attracted 70 delegates from nine countries, including investors from China, Korea and japan.

The event was officially opened by the Victorian Parliamentary Secretary for Medical Research and Small Business and Innovation, the Hon. Frank McGuire, who noted the sector is “creating jobs of future” and responsible for 200 clinical and pre-clinical trials underway currently in Victoria.  

Australia Biotech Invest 2017 will lift the profile of the Australian biotechnology industry and create access to greater funding sources for local companies to develop world-class science into therapies, diagnostics and medical devices.

The event includes a full-day program of company presentations, which will showcase the potential of life science companies and a dedicated exhibition area will enable companies to display detailed information about their business case and technologies and engage directly with prospective partners.

The event draws key decision makers from the investment community including venture capitalists, private equity firms and investment bankers, as well as from governments. The event merges market intelligence with investment opportunities and acts as a guide to successful biotech investment.

This year’s Australia Biotech Invest is supported by the Victorian Government and MTP Connect, and hosted by AusBiotech. Spotlight Company Presentations are supported by Morgans.

The event is part of the AusBiotech Global Investment Series, which forms part of borader project that has received funding the MTPConnect Project Fund Program to undertake a comprehensive global program for the Australian life sciences sector to give local life sciences companies a competitive advantage in attracting investment. Leading the Global Investment Program will cater to the needs of companies, investors and researchers in the life sciences and be assisted by consortium partners the ASX, DibbsBarker, WE Buchan and KPMG.

More information on today's presentation is available online.